APLI and APLIF Related Headlines
Go Back- Appili Therapeutics to Exhibit at World Vaccine Congress Washington
- Appili Therapeutics closes C$100,000 private placement second tranche
- Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
- Appili Therapeutics raises C$177,500 in first tranche of private placement
- Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
- Appili Therapeutics announces C$750,000 private placement
- Appili Therapeutics Announces Proposed Non-Brokered Private Placement
- Appili Therapeutics to Attend BARDA Innovation Symposium 2025
- NIAID awards Appili and Vitalex up to $40M for fungal vaccine development
- Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
- Appili Therapeutics shareholders elect six directors at annual meeting
- Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
- Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
- Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
- Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
- Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
APLI and APLIF Related Press Releases
Go Back- Appili Therapeutics to Exhibit at World Vaccine Congress Washington
- Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
- Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
- Appili Therapeutics Announces Proposed Non-Brokered Private Placement
- Appili Therapeutics to Attend BARDA Innovation Symposium 2025
- Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
- Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
- Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
- Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
- Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
- Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

